If someone suffers a heart attack while walking down the street and is taken to the hospital quickly, his/her chances of survival are very good. But if someone has a heart attack while already in the hospital for something else, he/she is 10 times more likely to die.


Patients with ruptured abdominal aortic aneurysms (AAA) are more than twice as likely to survive if they have minimally invasive repair than if they have surgery, suggests a 10-year study being.

CircuLite Inc. announced that it has received approval from the Federal Agency for Medicines and Health Products in Belgium to commence the CE mark trial of the Synergy IC Circulatory Support System, the first mechanical support system that does not require major surgery. The Synergy IC System is based on the surgical Synergy Circulatory Support System — the world’s smallest commercially available circulatory support pump — which is designed to treat ambulatory chronic heart failure patients (INTERMACS ?4).

A device commonly used to treat dangerous heart rhythms may cause more issues for patients than a simpler version of the same device. The implantable cardioverter-defibrillator (ICD) prevents sudden cardiac death by detecting irregularities and delivering an electrical jolt to restart the heart.

Can high blood pressure be safely reduced and controlled by “disconnecting” nerves in the kidneys? That is a question that a new clinical study called Symplicity HTN-3 at University Hospitals (UH) Case Medical Center hopes to answer. 

University of Maryland Medical Center Genetic-Testing Program Cardiac Stent

Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center (UMMC) now can receive long-term therapy based on information found in their genes. As part of a new personalized medicine initiative, the medical center is offering genetic testing to help doctors determine which medication a patient should take after a stenting procedure in order to prevent blood clots that could lead to serious or fatal heart attacks and strokes.

Prof. Dr. Béla Merkely and Dr. Péter Sótonyi at Semmelweis Egyetem Kardiológiai Központ in Hungary completed the first patient implant of the Barostim neo device for hypertension. Barostim neo is a small, easy to implant device manufactured by CVRx.

The Journal of American College of Cardiology has published the results from Corindus Vascular Robotics’ CorPath PRECISE (Percutaneous Robotic-Enhanced Coronary Intervention) study in the April 2013 issue. Results of the trial demonstrate the CorPath System is safe and feasible for patients, with significantly lower harmful radiation exposure to the operator.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now